Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Open in API
Filings indexed 830 across all filing types
Latest filing 2021-05-13 Earnings Release
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
FORM 424B3
Earnings Release Classification · 95% confidence The document is a Form 424B3 prospectus supplement related to a securities offering, which includes a current report on Form 8-K filed with the SEC. The Form 8-K contains a press release and presentation about the company's first quarter 2021 financial results, including detailed financial data such as revenue, net loss, cash position, and shares outstanding. It also announces a conference call and webcast for discussing these results. The presence of detailed financial results and analysis for a quarter, along with the timing (Q1 2021), indicates this is a quarterly earnings report. The document is not merely an announcement or a brief summary but contains substantive financial data and management commentary. Therefore, the appropriate classification is Earnings Release (ER).
2021-05-13 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated May 13, 2021. It announces the issuance of a press release and a presentation regarding the company's first quarter 2021 financial results. The document itself does not contain the full financial results but rather furnishes the press release and presentation as exhibits. The text explicitly states that the press release and presentation are furnished as exhibits and are not "filed" for purposes of the Exchange Act, indicating this document is an announcement of financial results rather than the results themselves. The document length is 4025 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS) because it is a current report announcing financial results and related materials but does not contain the full financial statements or detailed analysis itself.
2021-05-13 English
FORM DEFA14A
Remuneration Information Classification · 100% confidence The document is titled 'FORM DEFA14A' and references 'SCHEDULE 14A INFORMATION' and 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934.' It is marked as 'Definitive Additional Materials' related to a proxy statement. The DEFA14A form is specifically used for filings related to executive compensation and proxy solicitation materials. The content and form type clearly indicate this is a Remuneration Information filing, detailing compensation and related proxy materials for executives and directors.
2021-04-30 English
FORM DEF 14A
Proxy Solicitation & Information Statement
2021-04-30 English
SC 13G
Major Shareholding Notification
2021-04-19 English
FORM 424B3
Capital/Financing Update Classification · 95% confidence The document is a Form 424B3 prospectus supplement filed pursuant to SEC rules, which updates a prior prospectus related to an offering of common stock and warrants. It includes a current report on Form 8-K detailing an amendment to a collaboration and license agreement, including milestone payments and royalty terms. The document also contains a press release and a management presentation related to the amendment. The content focuses on financing and capital raising activities, specifically the offering of shares and warrants, and amendments to licensing agreements affecting payments and royalties. There is no detailed financial statement or comprehensive financial performance report, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a call transcript, board change, or legal proceeding. The primary focus is on capital raising and financing updates. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence level.
2021-04-08 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.